Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 9 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 11285139

    Treatment of CNS conditions

    Takeda Pharmaceutical Company Limited · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  2. US 11279713

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted
  3. US 11274101

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  4. US 11273182

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  5. US 11268154

    Methods for the identification, evaluation and treatment of patients having multiple myeloma

    Takeda Pharmaceutical Company Limited · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  6. US 11254731

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  7. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Takeda Pharmaceutical Company Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  8. US 11236099

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  9. US 11230541

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  10. US 11230545

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  11. US 11202776

    Treatment of gastroparesis with triazaspiro[4.5]decanone

    Takeda Pharmaceutical Company Limited · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  12. US 11197916

    Lyophilized recombinant VWF formulations

    Takeda Pharmaceutical Company Limited · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted
  13. US 11191837

    Recombinant VWF formulations

    Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  14. US 11191813

    Lyophilized recombinant VWF formulations

    Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  15. US 11191818

    Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

    Takeda Pharmaceutical Company Limited · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  16. US 11185575

    Subcutaneous administration of ADAMTS13

    Takeda Pharmaceutical Company Limited · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  17. US 11186565

    Aromatic compound

    Takeda Pharmaceutical Company Limited · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  18. US 11173161

    4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

    Takeda Pharmaceutical Company Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  19. US 11174272

    1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

    Takeda Pharmaceutical Company Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  20. US 11174301

    Peptide compound

    Takeda Pharmaceutical Company Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  21. US 11173147

    Prophylactic or therapeutic agent for delirium

    Takeda Pharmaceutical Company Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  22. US 11168083

    Inhibitors of Plasma Kallikrein and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  23. US 11160850

    Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

    Takeda Pharmaceutical Company Limited · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  24. US 11156612

    Methods of determining levels of cleaved and/or intact kininogen

    Takeda Pharmaceutical Company Limited · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted